z-logo
open-access-imgOpen Access
Effect of topiramate on sweat chloride level while screening for cystic fibrosis
Author(s) -
Roopa Siddaiah,
Eve Thau,
Gavin R. Graff
Publication year - 2018
Publication title -
bmj case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 26
ISSN - 1757-790X
DOI - 10.1136/bcr-2018-225697
Subject(s) - cystic fibrosis , medicine , topiramate , sweat , intensive care medicine , endocrinology , pediatrics , psychiatry , epilepsy
Cystic fibrosis is the most common life-limiting genetic condition in Caucasians caused by Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene mutations. Sweat chloride is the current gold standard for diagnosis where values >60 mmol/L are diagnostic and values >30 mmol/L are indeterminate. There is limited literature on the effect of medications on the sweat chloride values. We report a case of topiramate being responsible for false-positive testing which resulted in overutilisation of medical resources and psychosocial stress on the family. Topiramate should be considered during the interpretation of the gold standard testing as one of the cause of false-positive sweat tests.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here